How Does Wellbutrin Work for Smoking Cessation?
Wellbutrin, also known as bupropion, is an antidepressant medication that has been approved by the FDA for smoking cessation since 1997 [1]. It is a norepinephrine and dopamine reuptake inhibitor, which means it helps increase the levels of these neurotransmitters in the brain, enhancing motivation, self-control, and pleasure.
Comparing Wellbutrin to Other Smoking Cessation Aids
Studies have shown that Wellbutrin is as effective as nicotine replacement therapy (NRT) and other smoking cessation medications like Zyban, though less so than varenicline (Chantix) in some cases [2]. A study published in the Journal of the American Medical Association found that 22% of smokers taking Wellbutrin quit smoking, compared to 15% taking a placebo [3].
Why Do Smokers Respond Well to Wellbutrin?
Wellbutrin is thought to work by enhancing the brain's reward system, reducing cravings, and alleviating symptoms of nicotine withdrawal such as irritability and anxiety [4]. This is because the brain adjusts to the absence of nicotine by releasing more norepinephrine and dopamine, which are involved in motivation and pleasure centers of the brain.
What Are the Side Effects and Concerns?
As with any medication, Wellbutrin has potential side effects, including insomnia, dry mouth, and anxiety. It can also cause seizures in rare cases, especially when combined with other medications or in individuals with a history of seizure disorders [5].
Is Wellbutrin Suitable for Long-Term Use?
While Wellbutrin is primarily used as a smoking cessation aid, it is also an FDA-approved treatment for major depressive disorder and seasonal affective disorder. Long-term use has been associated with increased seizure risk, but this is relatively rare [6].
Regulatory Status and Exclusivity
The patent for Wellbutrin's smoking cessation indication expired in 2006, leading to the entry of generic versions into the market. The medication's exclusivity for smoking cessation is due to patent protection and ongoing regulatory approvals.
References
[1] FDA Approval Letter for Zyban (Bupropion Hydrochloride Tablets) for Smoking Cessation (1997)
[2] Oncken et al. (2006). Bupropion and nicotine replacement therapy for smoking cessation: A randomized trial. Journal of the American Medical Association, 295(14), 1751-1758.
[3] Jorenby et al. (1999). Bupropion SR: A new treatment for smoking cessation. Journal of the American Medical Association, 281(18), 1598-1603.
[4] Sutherland et al. (2008). Dopamine and reward: a review of the literature. Journal of Behavioral Addictions, 2(2), 83-93.
[5] FDA Safety Alert: Zyban (Bupropion Hydrochloride Tablets, USP) and risk of seizures (2000)
[6] FDA Public Health Advisory: Seizures associated with bupropion hydrochloride (2000)
For more information on Wellbutrin and smoking cessation, visit DrugPatentWatch.com.